With reference to the report published by the professionals the scope of the global Clinical Oncology Next Generation Sequencing (NGS) Market was projected on US$ 627.2 million in 2018. It is estimated to grow by a CAGR of 13.2% for the duration of the forecast and to touch US$ 1.5 billion by the completion of 2025.
Market Overview:
Substantial growth in the
acceptance of genome-focused pharmacology for the treatment of cancer is
estimated to deliver opportunities of development for the market. Clinical
Oncology NGS functions such as one of the greatly advanced genomic procedures
for the examination of transformations that cause development of the cancer.
Request free sample to get a complete analysis of top-performing
companies @ https://www.millioninsights.com/industry-reports/clinical-oncology-next-generation-sequencing-ngs-market/request-sample
Key Players:
-
Qiagen N.V., Partek, Inc., Paradigm Diagnostics,
Pacific Bioscience, Perkin Elmer, Myriad Genetics, F. Hoffmann-La Roche Ltd,
Eurofins Scientific S.E, Caris Life Sciences
Growth Drivers:
The development of the clinical
oncology next generation sequencing market is complemented by the reduction in
the price of genetic sequencing, progressions in the arena of oncology and
custom-made medication, growth in the occurrence of cancer, all over the world
and development in the acceptance of this method above single-gene testing. As
this method is additionally dependable than Sanger sequencing for diagnosis,
the market is estimated to observe considerable development during the period
of forecast.
Leap forward progressions in the
expansion of genetic centered examinations for oncology and additional
complaints for the duration of the previous a small number of years have
considerably driven the development of the market. The advanced technology of
sequencing proposes a superior understanding of lump, therefore permitting the
designing of balance medication. Therefore, additional products are estimated
to become commercialized during the nearby period.
Clinical Oncology NGS Technology Outlook (Revenue, USD Million, 2014 -
2025)
• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing & Resequencing
The global clinical oncology NGS
market can be classified by End Use, Application, Workflow, Technology and
Region. By End Use, it can be classified as Laboratories, Clinic &
Hospitals, Academic Research, Clinical Research, and Biotech & Pharmaceutical
Units. By Application it can be classified as Companion Diagnostics, Screening
and Others. By Work flow, it can be classified as NGS Data Analysis, NGS
Pre-Sequencing, and NGS Sequencing. By Technology it can be classified as
Targeted Sequencing & Resequencing, Whole Genome Sequencing, and Whole
Exome Sequencing.
Browse Related Category Research Reports @ https://millioninsightsmarket.wordpress.com
No comments:
Post a Comment